Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Severe Bacterial Non-AIDS Infections in Persons With Human Immunodeficiency Virus: The Epidemiology and Evolution of Antibiotic Resistance Over an 18-Year Period (2000-2017) in the ANRS CO3 AquiVih-Nouvelle-Aquitaine Cohort.
Blanc P, Bonnet F, Leleux O, Perrier A, Bessede E, Pereyre S, Cazanave C, Neau D, Vareil MO, Lazaro E, Duffau P, Saunier A, André K, Wittkop L, Vandenhende MA; ANRS CO3 AquiVih-Nouvelle-Aquitaine Cohort Study Group. Blanc P, et al. Among authors: perrier a. Clin Infect Dis. 2023 May 24;76(10):1814-1821. doi: 10.1093/cid/ciac978. Clin Infect Dis. 2023. PMID: 36610063
Statin use and risk of severe bacterial infection in a population living with HIV: prospective cohort study of the ANRS CO3 Aquitaine Cohort 2000-2018.
Teruel E, Vandenhende MA, Neau D, Lazaro E, Duffau P, Vareil MO, Cazanave C, Perrier A, le Marec F, Leleux O, Bonnet F, Wittkop L. Teruel E, et al. Among authors: perrier a. Clin Microbiol Infect. 2021 Sep;27(9):1301-1307. doi: 10.1016/j.cmi.2020.11.019. Epub 2020 Dec 1. Clin Microbiol Infect. 2021. PMID: 33276140 Free article.
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Nyamankolly E, Bellecave P, Wittkop L, Le Marec F, Duffau P, Lazaro E, Vareil MO, Tumiotto C, Hessamfar M, Cazanave C, Perrier A, Leleux O, Bonnet F, Neau D. Nyamankolly E, et al. Among authors: perrier a. Int J Antimicrob Agents. 2023 Jan;61(1):106696. doi: 10.1016/j.ijantimicag.2022.106696. Epub 2022 Dec 2. Int J Antimicrob Agents. 2023. PMID: 36470511
Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV).
Devos S, Bonnet F, Hessamfar M, Neau D, Vareil MO, Leleux O, Cazanave C, Rouanes N, Duffau P, Lazaro E, Dabis F, Wittkop L, Barger D; ANRS CO3-AQUIVIH-NA-QuAliV. Devos S, et al. BMC Infect Dis. 2023 Jan 9;23(1):16. doi: 10.1186/s12879-022-07963-6. BMC Infect Dis. 2023. PMID: 36624391 Free PMC article.
External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
Surial B, Ramírez Mena A, Roumet M, Limacher A, Smit C, Leleux O, Mocroft A, van der Valk M, Bonnet F, Peters L, Rockstroh JK, Günthard HF, Berzigotti A, Rauch A, Wandeler G; Swiss HIV Cohort Study; ATHENA Observational Cohort Study; EuroSIDA; ANRS CO3 Aquitaine Cohort. Surial B, et al. J Hepatol. 2023 May;78(5):947-957. doi: 10.1016/j.jhep.2022.12.029. Epub 2023 Jan 21. J Hepatol. 2023. PMID: 36690280 Free article.
Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study).
Ben Farhat J, Hessamfar M, Farbos S, Desclaux A, Dumondin G, Ferrand H, Greib C, Castan B, Rispal P, Duffau P, Leleux O, Perrier A, Wittkop L, Bonnet F, Barger D. Ben Farhat J, et al. Among authors: perrier a. J Acquir Immune Defic Syndr. 2024 Jan 1;95(1):1-5. doi: 10.1097/QAI.0000000000003310. J Acquir Immune Defic Syndr. 2024. PMID: 37757852
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, Rauch A, Mugglin C, Klein M, van der Valk M, Smit C, Jarrin I, Berenguer J, Lacombe K, Requena MB, Wittkop L, Leleux O, Bonnet F, Salmon D, Matthews GV, Guy R, Martin NK, Spelman T, Prins M, Stoove M, Hellard M; InCHEHC Collaboration. Sacks-Davis R, et al. Lancet HIV. 2024 Feb;11(2):e106-e116. doi: 10.1016/S2352-3018(23)00267-9. Epub 2024 Jan 12. Lancet HIV. 2024. PMID: 38224708
Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).
Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, Spire B, Todesco E, Bouchaud O, Fagard C, Chene G, Girard PM; ANRS 140 DREAM Study Group. Meynard JL, et al. J Antimicrob Chemother. 2018 Jun 1;73(6):1672-1676. doi: 10.1093/jac/dky055. J Antimicrob Chemother. 2018. PMID: 29584910 Clinical Trial.
490 results